Summit Therapeutics PLC (LON:SUMM)

Summit Therapeutics PLC (LON:SUMM)

Share Price
19.50 p
0 (0.00 %)
Market Cap
£16.04 m
Proactive Investors - Run By Investors For Investors

Summit Therapeutics PLC

Summit Therapeutics is a leader in antibiotic innovation.

We have a clear strategy: through new science and philosophy, we are creating new opportunities to become the standard of care for serious infectious diseases.

Market: AIM:SUMM
52-week High/Low: 245.00p / 19.00p
Sector: Pharma & Biotech
Market Cap: 16.04M
col 3
col 4
col 5
col 6

Big picture - Why invest in Summit Therapeutics PLC

Summit Therapeutics PLC Timeline

- Key inflection point: topline data readout from the PhaseOut DMD phase 2 trial in Duchenne (DMD) expected in 3Q 2018 - Imminent start of a pivotal phase 3 study for ridinilazole in C. difficile infections (CDI) - Recent Discuva acquisition reinforces novel antibiotics discovery capabilities  - Current...
The recently announced positive interim data from PhaseOut DMD showed that after 24 weeks of treatment, there was a significant and meaningful reduction in muscle damage, as well as a significant reduction in muscle inflammation, in patients treated with ezutromid

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use